ORLANDO, Fla. — The interleukin (IL)-4 and IL-13 inhibitor dupilumab improved itch symptoms and curtailed disease activity while also reducing oral corticosteroid use in older patients with bullous pemphigoid (BP), a phase 2/3 study demonstrated. “Dupilumab demonstrated significant benefits across multiple disease aspects in BP at 36 weeks...
GET PAID FOR SHOPPING AT ALL YOUR FAVORITE STORES!
Sound too good to be true? Here’s the deal: Stores pay us a commission for sending you their way.
We share that with you as Cash Back. Everyone wins! SIGN UP FOR FREE!
.png)
COOL ROOM ENTERTAINMENT 10530 Campus Way South #1174 Largo, MD 20774
(916) 619-1308
teosmoot@gmail.com
Copyright © 2024 Cool Room Entertainment. All Rights Reserved
